Ambroxol is expected to improve the signs and symptoms of patients with Type I Gaucher
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT01463215
Ages eligible for Study
16 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Biochemically and genetically confirmed diagnosis of Gaucher disease caused by β-glucocerebrosidase deficiency resulting from mutations in the GBA genes, which have been shown to respond to Ambroxol according to in vitro screening assay.
Must be 16 years of age or older at the time of study initiation.
With an intact, enlarged spleen.
A hemoglobin level of at least 10 g/L.
Able to understand and cooperate with the requirements of the study protocol.
Mentally competent, have ability to understand and willingness to sign the informed consent form.
Able to travel to a participating study site.
Women of child-bearing potential must use accepted contraceptive methods, and must have a negative serum or urine pregnancy test within one week prior to treatment initiation. An additional pregnancy test is to be performed, and results obtained, prior to administration of the first dose of Ambroxol.
Fertile men must practice effective contraceptive methods during the study period, unless documentation of infertility exists.
Body weight >40 kg (88 lbs).
Receipt of any form of glucocerebrosidase <<4 weeks prior study initiation.
Serious medical illness, significant cardiac disease, chronic bronchitis, emphysema, and cystic fibrosis, as well as disorders causing ventilation perfusion mismatch.
Any complex disease that may confound treatment assessment.
Pregnant women, or women of child-bearing potential not using reliable means of contraception.
Lactating females because of the potential for adverse reactions in nursing infants.
Fertile men unwilling to practice contraceptive methods during the study period.
Unwilling or unable to follow protocol requirements.
Known hypersensitivity reactions, intolerance or adverse reactions to Ambroxol or to the inactive ingredients.
Evidence of systemic infection, or serious infection within the past month.
Known to have HIV infection.
Known to have hepatitis B or hepatitis C.
Patients with a history of convulsive disorders.
Patients receiving any other investigational treatment for any indication within the past 4 weeks prior to initiation of Ambroxol treatment.
A history of cancer of any type.
Patients who have received immunotherapy of any type within the past 4 weeks prior to study initiation.
Any condition or abnormality which may, in the opinion of the investigator, compromise the safety of patients.
All locations for NCT01463215
United States (1)
Monmouth Junction, New Jersey, United States, 08852
View full eligibility
Tris trial is registered with FDA with number: NCT01463215. The sponsor of the trial is Exsar Corporation and it is looking for 20 volunteers for the current phase.
Official trial title: An Open-Label, Dose Escalation With 2 Dose Levels, Proof-of-Concept Clinical Trial of Ambroxol for the Treatment of Type I Gaucher Disease
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.